PA
ATRO icon

PharVision Advisers’s Astronics ATRO Stock Holding History

PharVision Advisers’s Portfolio ATRO Stock Details ATRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,091
Closed -$456K – 142
2025
Q4 		$456K Buy
+10,091
New +$423K 0.23% 64
2025
Q3 		– Sell
-7,657
Closed -$214K – 668
2025
Q2 		$214K Buy
+7,657
New +$179K 0.31% 181

Other funds holding ATRO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PharVision Advisers's ATRO Position: Q1 2026 in Review

PharVision Advisers sold out of Astronics (ATRO) in Q1 2026, closing a stake of 10,091 shares — an estimated $456K sold.

PharVision Advisers first reported a position in ATRO in Q2 2025 and held it in 2 quarters. The position peaked at $456K in Q4 2025. 293 funds tracked by Wall St. Rank hold ATRO as of Q1 2026.

  • PharVision Advisers reported no remaining Astronics position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 10,091 Astronics shares in Q1 2026, an estimated $456K.
  • PharVision Advisers first reported a position in Astronics in Q2 2025 and held it in 2 quarters.
  • PharVision Advisers's Astronics position peaked at $456K in Q4 2025.
  • 293 funds tracked by Wall St. Rank held Astronics as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.